At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 146 enrolled
Drug / intervention
TransCon hGHdrug
Likely dose
TransCon hGH 0.24 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
fliGHt: A Multicenter, Phase 3, Open-Label, 26-Week Trial Investigating the Safety, Tolerability and Efficacy of TransCon hGH Administered Once Weekly in Children With GHD
In Brief
A Phase 3 clinical trial evaluating TransCon hGH for Growth Hormone Deficiency, Pediatric and 3 related conditions. Completed, enrolled 146 participants across 24 sites in 4 countries.
Detailed Summary
A 26 week trial of TransCon hGH, a long-acting growth hormone product, administered once-a-week. Approximately 150 children (males and females) with growth hormone deficiency (GHD) will be included. All study participants will receive TransCon hGH. This is a global trial that will be conducted in, but not limited to, the United States, Canada, Australia, and New Zealand.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGrowth Hormone Deficiency, Pediatric, Endocrine System Diseases, Hormone Deficiency, Pituitary Diseases
CountriesAustralia, Canada, New Zealand, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedOct 2017
Enrollment StartNov 2017
Primary CompletionMar 2019
TodayJul 2026
First PostedOct 9, 2017
Enrollment StartNov 13, 2017
Primary CompletionMar 19, 2019
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 8.7 years ago
Interventions
TransCon hGHdrug
Once weekly subcutaneous injection at a starting dose of 0.24 mg/kg/week